Appointments Strengthen Expertise in Immunotherapy of Cancer
BETHESDA, Md., March 19 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the the appointment of Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Other members of the company's advisory panel include professors Richard Flavell (Yale University), Michael Keating (MD Anderson), Ronald Levy (Stanford University), Jeffrey Ravetch (Rockefeller University), and Anthony Tolcher (START).
Sir Walter Bodmer holds a Ph.D. degree from Cambridge University, UK, and, among several other appointments, was Chair of Genetics of Oxford University, Director-General of the Imperial Cancer Research Fund (ICRF), President of the International Human Genome Organization (HUGO), President of the British Association for the Advancement of Science, and Chancellor of the University of Salford. He retired as Principal of Hertford College, Oxford, where he continues scientific work at the Cancer and Immunogenetics Laboratory of the Weatherall Institute. Sir Walter Bodmer did seminal work in the area of bacterial genetics, molecular and biochemical analysis of the HLA system and its association with disease, differentiation and malignant transformation of colonic epithelial cells, and has profound expertise in immunotherapeutic targets CEA and EpCAM, which are being targeted by Micromet's product candidates adecatumumab, MT110 and MT111/MEDI-565.
Bernard Fox is President of the International Society for the Biological Therapy of Cancer, and Chief of the Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research CenterPage: 1 2 3 4 5 Related biology technology :1
. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference2
. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum3
. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings4
. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference5
. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 20076
. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors7
. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 20078
. Micromet to Present at Two Upcoming Investor Conferences9
. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 200810
. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results11
. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results